Please assess the completion status of the following clinical trial:

Trial Title: Baby Vaccine Study (Sched3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants due to receive their primary immunisations , aged up to 13 weeks on first vaccinations.~* Written informed consent given by mother who is aged \>= 16 years \[NB mother is preferable as consent also allows permission to record the date of pertussis immunisation in pregnancy, which may need to be verified in her medical record. Where mother is not available, consent may be taken from father or legal guardian and maternal pertussis status noted as not known\]~Exclusion Criteria:~* Bleeding disorder~* Fulfil any of the contraindications to vaccination as specified in The Green Book \[https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book\]:~* At risk of invasive pneumococcal disease (IPD) as defined in the Green Book pneumococcal chapter and those born prior to 37 weeks gestation~* Confirmed anaphylactic reaction to a previous dose of the vaccine, or~* Confirmed anaphylactic reaction to any constituent or excipient of the vaccine(s).~* A confirmed anaphylactic reaction to neomycin, streptomycin or polymyxin B (which may be present in trace amounts in the tetanus vaccine) and/or kanamycin, histidine, sodium chloride or sucrose (which may be present in trace amounts in the MenB vaccine).~* Latex hypersensitivity (the syringe cap of Bexsero may contain natural rubber latex)

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: OTHER): Group 1 will receive the following interventions:~* DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~* 13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months~* Rotavirus vaccine oral 1.5ml at 2 and 3 months~* 4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~* Meningococcal C/Hib vaccine IM 0.5ml at 12 months~* Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months
- Group 2 (Type: OTHER): Group 2 will receive the following interventions:~* DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~* 13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)~* Rotavirus vaccine oral 1.5ml at 2 and 3 months~* 4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~* Meningococcal C/Hib vaccine IM 0.5ml at 12 months~* Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months

Based on this trial design, predict the completion outcome and termination type (if applicable).